The education library
Testosterone enanthate: medical uses, evidence and risks
Educational evidence summary, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review completed. Current Canadian product authorization is not established by this article.
What the name means
Testosterone enanthate is an ester of testosterone. The ester changes how a formulation releases the hormone; the body subsequently separates it to release testosterone. It is not a separate class of hormone with wholly different effects. “Testosterone” can mean the hormone itself, the medicine category, or a particular formulation, so those terms should not be treated as interchangeable in a research claim. The Hikma prescribing information describes this conversion and the longer duration produced by esterification. Hikma prescribing information
Medical history and purpose
The US prescribing information for Xyosted, an enanthate formulation, records initial US approval in 1953. That is historical US information, not evidence of present Canadian authorization for every brand. Its current indication is replacement therapy for adult males with conditions causing deficient or absent endogenous testosterone. A long history of medical use does not mean every proposed use has been tested, or that every preparation shares the same supporting studies. Xyosted prescribing information
Understanding deficiency before discussing benefits
Hypogonadism is a clinical diagnosis rather than a description of tiredness alone. The Endocrine Society recommends compatible symptoms or signs together with consistently low testosterone, confirmed through repeat morning testing. Investigation distinguishes testicular causes from problems in the hypothalamus or pituitary. This matters because treating a symptom without understanding its cause can miss another condition. Replacement can be appropriate for confirmed deficiency; that does not make testosterone a general remedy for ageing or low energy. Endocrine Society clinical guideline, 2018
What human studies actually show
Sexual symptoms and wellbeing
The Testosterone Trials enrolled 790 men aged 65 or older with low testosterone and relevant symptoms. Over one year, testosterone gel improved sexual activity, sexual desire and erectile function compared with placebo. Mood and depressive symptoms improved modestly. The primary vitality outcome did not improve significantly. These differences are useful: a benefit for one symptom is not evidence for a universal improvement in energy, motivation or quality of life.
This was a study of gel in a selected older population. It informs the discussion of testosterone replacement but does not establish an enanthate-specific effect of the same size, nor a benefit in people whose testosterone is normal. Snyder and colleagues, NEJM, 2016
Cardiovascular outcomes: a narrower answer than “safe”
TRAVERSE studied replacement therapy in men with hypogonadism and existing cardiovascular disease or elevated cardiovascular risk. The primary cardiovascular outcome occurred in 7.0% of the testosterone group and 7.3% of the placebo group. The result met the trial's noninferiority criterion. Atrial fibrillation, acute kidney injury and pulmonary embolism were observed more often with testosterone.
The trial used gel and followed participants for a mean of about 33 months. It does not establish lifelong safety, prevention of heart disease, or safety of nonmedical use. “No excess in the trial's primary composite outcome” is a more accurate reading than “no cardiovascular risks.” Lincoff and colleagues, NEJM, 2023
Bone outcomes: strength of evidence matters
A fracture analysis involving 5,204 TRAVERSE participants did not show fracture prevention. Clinical fractures occurred in 3.50% of testosterone-treated participants and 2.46% of placebo-treated participants over a median 3.19 years. The hazard ratio was 1.43, with a 95% confidence interval of 1.04–1.97.
A change in a biological measurement should not automatically be presented as an improvement in a patient-important outcome. For someone concerned about fractures, this study is a reason to ask about a dedicated bone-health assessment rather than assume testosterone supplies protection. Again, this was gel research, not an enanthate-specific fracture trial. Snyder and colleagues, NEJM, 2024
Risks worth understanding
Blood pressure
In February 2025 the FDA announced class-wide labelling changes following TRAVERSE and ambulatory blood-pressure studies. It removed boxed-warning language about increased adverse cardiovascular outcomes while requiring blood-pressure warnings. The age-related hypogonadism limitation remained. Removing one warning is not equivalent to removing the need to assess cardiovascular health. This is a US regulatory update, not a Canadian label change. FDA, 28 February 2025
Blood, breathing, fertility and mood
The Xyosted label identifies increased red-cell concentration, venous blood clots, sleep-apnoea concerns, fluid retention, lipid changes and suppression of sperm production. It also flags depression and suicidal thoughts. Pregnancy exposure can harm a fetus. These are reasons for individualized clinical assessment rather than reassurance based on how someone feels. Some adverse effects require tests to detect; absence of obvious symptoms is not proof of absence of harm. Xyosted prescribing information, revised July 2025
Skin and other effects
The Hikma label lists acne, hair changes, breast enlargement, changes in libido, anxiety and depression among possible adverse reactions. It also describes fluid retention and abnormalities involving the liver. A label's list does not supply an individual probability of each event; formulation, underlying illness and the circumstances of exposure matter. Hikma prescribing information
Interactions and people needing particular caution
The Hikma label describes interactions involving oral anticoagulants, diabetes medicines and insulin, and corticosteroids or ACTH. These can affect bleeding-related monitoring, blood glucose or fluid retention. A clinician or pharmacist needs the complete medicine list, including nonprescription products; readers should not adjust another medicine to compensate on their own. Hikma prescribing information
The Endocrine Society recommends against starting testosterone in several circumstances, including plans for near-term fertility, elevated haematocrit, untreated severe obstructive sleep apnoea, uncontrolled heart failure, recent heart attack or stroke, thrombophilia and certain prostate or breast findings. The guideline also advises against prescribing it specifically to improve blood-glucose control in type 2 diabetes. These are clinical screening issues, not a checklist for self-clearance. Endocrine Society clinical guideline, 2018
Canadian context
Testosterone appears in item 23 of Schedule IV of Canada's Controlled Drugs and Substances Act, under anabolic steroids and their derivatives. That classification alone does not establish whether a particular brand is currently marketed, what its approved indication is, or which rules apply to a particular transaction. Department of Justice, Schedule IV; consolidation current to 30 September 2026
Research limitation: Health Canada's database identifies a Delatestryl product record, but its detail page failed during this review. Its current marketing status and Canadian product monograph have not been verified. No claim of present Canadian availability is made here. Health Canada product record to verify
Reading claims with a critical eye
Three questions help separate useful evidence from confident marketing: Was the study conducted in people with a diagnosed deficiency? Did it test this formulation? Did it measure an outcome that matters to patients, or only an intermediate measurement? The studies above answer different questions and should remain separate in a reader's mind. An anecdote about feeling better cannot settle an unanswered long-term safety question.
For a medical discussion, useful questions include: What explains my symptoms? Which benefits are plausible for my diagnosis? How will response and adverse effects be assessed? Does the plan account for fertility and my other medicines? Those questions make the evidence more useful without turning a general article into an individualized prescription.